Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 8/2015

01-08-2015 | Research Article

Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12

Authors: Zongtao Xie, Liming Cai, Runsheng Li, Jinyu Zheng, Hongyan Wu, Xiaoqi Yang, Hu Li, Zhiqiang Wang

Published in: Tumor Biology | Issue 8/2015

Login to get access

Abstract

microRNAs are small, non-coding RNAs that contribute into various biological processes during cancer progression. However, the potential role of miR-489 in the development of Non-Small Cell Lung Cancer (NSCLC) is not demonstrated. In present study, miR-489 was down-regulated both in tumor tissues and cells. Inhibition of miR-489 promoted cells invasion by using an invasion assay. Furthermore, miR-489 could regulate SUZ12 as shown by luciferase reporter and Western blot assays. Aberrant miR-489 expression could regulate the molecular changes (E-cadherin, N-cadherin, and Vimentin) of epithelial mesenchymal transition (EMT). In conclusion, our study revealed that miR-489 may play an essential role in the progression of NSCLC.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61:69–90.
2.
Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000-02 period analysis of eurocare-4 data. Lancet Oncol. 2007;8:784–96.CrossRefPubMed
3.
Osada H, Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene. 2002;21:7421–34.CrossRefPubMed
4.
Cheng L, Yang T, Kuang Y, Kong B, Yu S, Shu H, et al. Microrna-23a promotes neuroblastoma cell metastasis by targeting cdh1. Oncol Lett. 2014;7:839–45.PubMedPubMedCentral
5.
Miao L, Xiong X, Lin Y, Cheng Y, Lu J, Zhang J, et al. Mir-203 inhibits tumor cell migration and invasion via caveolin-1 in pancreatic cancer cells. Oncol Lett. 2014;7:658–62.PubMedPubMedCentral
6.
Esquela-Kerscher A, Slack FJ. Oncomirs - micrornas with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMed
7.
Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y, et al. Microrna-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting myb. Cancer Lett. 2014;347:65–74.CrossRefPubMed
8.
8 Yang Y, Meng H, Peng Q, Yang X, Gan R, Zhao L, Chen Z, Lu J, Meng QH: Downregulation of microrna-21 expression restrains non-small cell lung cancer cell proliferation and migration through upregulation of programmed cell death 4. Cancer gene therapy 2014.
9.
Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, Gel B, et al. Mir-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903–9.CrossRefPubMed
10.
Lei L, Huang Y, Gong W. Mir-205 promotes the growth, metastasis and chemoresistance of nsclc cells by targeting pten. Oncol Rep. 2013;30:2897–902.PubMed
11.
Xu TP, Zhu CH, Zhang J, Xia R, Wu FL, Han L, et al. Microrna-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. Asian Pacific J Cancer Prevent : APJCP. 2013;14:7085–90.CrossRef
12.
Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for ezh2 histone methyltransferase activity. EMBO J. 2004;23:4061–71.CrossRefPubMedPubMedCentral
13.
Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of mir-200 inhibition of suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010;39:761–72.CrossRefPubMedPubMedCentral
14.
Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, et al. Suz12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing hrk. Molec Cancer Res : MCR. 2012;10:1462–72.CrossRef
15.
Martin-Perez D, Sanchez E, Maestre L, Suela J, Vargiu P, Di Lisio L, et al. Deregulated expression of the polycomb-group protein suz12 target genes characterizes mantle cell lymphoma. Am J Pathol. 2010;177:930–42.CrossRefPubMedPubMedCentral
16.
Liu C, Shi X, Wang L, Wu Y, Jin F, Bai C, et al. Suz12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol : J Int Soc Oncodev Biol Med. 2014;35:6073–82.CrossRef
17.
Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, Labarge MA, You L, Kogan SC, Gray JW, Mao JH, Wei G: Cul4a induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating zeb1 expression. Cancer Res 2013.
18.
Liu J, Ruan B, You N, Huang Q, Liu W, Dang Z, et al. Downregulation of mir-200a induces emt phenotypes and csc-like signatures through targeting the beta-catenin pathway in hepatic oval cells. PLoS One. 2013;8:e79409.CrossRefPubMedPubMedCentral
19.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442–54.CrossRefPubMed
20.
da Silva SD, Alaoui-Jamali MA, Soares FA, Carraro DM, Brentani HP, Hier M, et al. Twist1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target. Cancer. 2014;120:352–62.CrossRefPubMed
21.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: Cancer J Clin. 2013;63:11–30.
22.
Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth g.H.A. Clowes memorial award lecture. Cancer Res. 1990;50:6130–8.PubMed
23.
Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microrna expression profiling in non small cell lung cancer. Lung Cancer. 2013;81:388–96.CrossRefPubMed
24.
Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ. Down-regulation of the mirna-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates emt is involved in cancer progression. Neoplasia. 2013;15:180–91.CrossRefPubMedPubMedCentral
25.
Ouyang H, Gore J, Deitz S, Korc M: Microrna-10b enhances pancreatic cancer cell invasion by suppressing tip30 expression and promoting egf and tgf-beta actions. Oncogene 2013.
26.
Kitamura K, Seike M, Okano T, Matsuda K, Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K, Gemma A: Mir-134/487b/655 cluster regulates tgf-beta-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting magi2 in lung adenocarcinoma cells. Mol Cancer Ther 2013.
27.
Benoit YD, Witherspoon MS, Laursen KB, Guezguez A, Beausejour M, Beaulieu JF, et al. Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Exp Cell Res. 2013;319:1463–70.CrossRefPubMed
Metadata
Title
Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12
Authors
Zongtao Xie
Liming Cai
Runsheng Li
Jinyu Zheng
Hongyan Wu
Xiaoqi Yang
Hu Li
Zhiqiang Wang
Publication date
01-08-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3340-3

Other articles of this Issue 8/2015

Tumor Biology 8/2015 Go to the issue

Research Article

Impact of TGF-β1 -509C/T and 869T/C polymorphisms on glioma risk and patient prognosis

Research Article

Astemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCC

Research Article

Association between SNPs in Serpin gene family and risk of esophageal squamous cell carcinoma

Research Article

Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy

Research Article

Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer

Research Article

Vitamin D receptor gene polymorphisms and breast cancer risk among postmenopausal Egyptian women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits